Roxane Labrosse, Julia Chu, Myriam Armant, John K Everett, Danilo Pellin, Niharika Kareddy, Andrew L Frelinger, Lauren A Henderson, Amy E O'Connell, Amlan Biswas, Jet Coenen-van der Spek, Alexandra Marina Miggelbrink, Claudia Fiorini, Hriju Adhikari, Charles C Berry, Vito Adrian Cantu, Johnson Fong, Jason Roy Jaroslavsky, Derin F Karadeniz, Quan-Zhen Li, Shantan Reddy, Aoife M Roche, Chengsong Zhu, Jennifer S Whangbo, Colleen Dansereau, Brenda L Mackinnon, Emily Morris, Stephanie M Koo, Wendy B London, Safa Baris, Ahmet Ozen, Elif Karakoc-Aydiner, Jenny McDade Despotovic, Lisa R Forbes Satter, Akihiko Saitoh, Yuta Aizawa, Alejandra King, Mai Anh T Nguyen, Vy Do Uyen Vu, Scott B Snapper, Anne Galy, Luigi D Notarangelo, Frederic D Bushman, David A Williams, Sung-Yun Pai
Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder characterized by combined immunodeficiency, eczema, microthrombocytopenia, autoimmunity, and lymphoid malignancies. Gene therapy (GT) to modify autologous CD34+ cells is an emerging alternative treatment with advantages over standard allogeneic hematopoietic stem cell transplant for patients who lack well-matched donors, avoiding graft-versus-host-disease. We report the outcomes of a phase I/II clinical trial in which 5 patients with severe WAS underwent GT using a self-inactivating lentiviral (SIN-LV) vector expressing the human WAS cDNA under the control of a 1...
July 21, 2023: Blood